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Background: The present study attempted to provide information regarding non-muscle myosin II (MII) isoforms 
immunoreactivity in patients with head and neck squamous cell carcinoma (HNSCC) and analysis of the patients’ 
clinical status after 5 years of monitoring. 
Material and Methods: A semiquantitative analysis of the immunoreactivity of the MII isoforms was performed 
in 54 surgical specimens and its correlation with clinical and pathological variables and prognosis was verified. 
Data were analyzed using chi-square, Mann-Whitney and Kruskal-Wallis tests. To evaluate the survival over the 
total monitoring time and any connection with the proteins studied, the Kaplan-Meier analysis was used. P values 
≤0.05 were considered statistically significant. 
Results: In the advanced stages of pathological tumor-node-metastasis, the expression of MIIB in adjacent non-
neoplastic epithelial tissues tended to increase (p = 0.057). In tumoral zones there was an association of high 
expression among the three isoforms (MIIA/MIIB p=0,001, MIIB/MIIC p=0,006 and MIIA/MIIC p=0,012). 
Negative clinical evolution in patients was directly correlated to increased MIIC expression in the tumoral zone 
of invasion in HNSCC (p = 0.017). Based on clinical evolution after the monitoring period, patients with tumors 
expressing MIIC had poorer prognoses (p = 0.048). 
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Introduction
Squamous cell carcinoma, a disease linked to risk fac-
tors such as tobacco and alcohol consumption, is the 
most common malignant neoplasm of the head and neck 
(HNSCC). In addition to these major risk factors, sun 
exposure, eating habits and types 16 and 18 of human 
papillomavirus (HPV) are related to the pathogenesis 
of the disease, mostly in the oropharynx (1). Despite 
advancements in treatment, the mortality rate of HN-
SCC continues to be high and the survival rate low (2). 
Tools for provision of prognostic information for pa-
tients suffering from malignant neoplasia, such as his-
tological grading and the TNM system, are questioned 
by some studies since a solid tumor such as HNSCC 
presents an uneven cellular population, resulting in dif-
ferent behaviors in distinct tumor zones, often masking 
the real degree of progression of the disease (3). The 
causes of treatment failure and poor prognosis include 
tissue invasion and development of metastatic poten-
tial, which is regulated by molecular alterations such as 
modifications to cellular adhesion to the extracellular 
environment, allowing displacement of the cell, an in-
dispensable process for tumor progression (4,5). Among 
the molecules involved in cellular locomotion, type II 
non-muscle myosin (MII) plays a key role in regula-
tion of different migratory events through generation of 
contractile forces that align actin filaments and control 
adhesion maturation, nucleus displacement, and cellu-
lar body retraction during cytokinesis (3,5). The pres-
ent study attempted to provide information concerning 
the immunohistochemical expression of MII isoforms 
(A, B, and C) in patients with HNSCC through evalu-
ation of MII immunoreactivity in surgical specimens, 
and analysis of patient clinical status after 5 years of 
monitoring.
Material and Methods
-Description of the Sample
This sample is composed by 54 patients included in a 
previous study approved by the Research Ethics Com-
mittee of the Porto Alegre Clinical Hospital (HCPA) on 
August 28, 2009 (09-315). The collection lasted twelve 
months from October 2009 and was composed by pa-
tients diagnosed with HNSCC and treated at the Sur-
gery Ambulatory of Head and Neck in the HCPA. All 
individuals were older than 18 years at the time of diag-
nosis, and they each signed an informed consent form as 
Conclusions: The present study suggests that MIIB expression in non-neoplastic adjacent epithelial tissues may 
indicate a potential for regional metastasis and that MIIC expression in the tumoral zone of invasion is predictive of 
negative evolution of the disease. 
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well as answered a survey used to obtain demographic 
data such as age, gender and deleterious habits includ-
ing tobacco and alcohol. Paraffin blocks were prepared 
with the HNSCC samples and the tumor clinical data 
was performed at the time of surgery (6). After this, 
these patients were followed up until July 2015.
-Evaluation of Tumor Samples
Histological cuts of 3 µm were obtained from the par-
affin blocks prepared earlier (6) and stained with he-
matoxylin and eosin. For each HNSCC sample, tumoral 
zones were identified as the center of the tumor (CT) 
and the zone of invasion (ZI), as well as non-neoplastic 
adjacent epithelial tissues (AE) (7) (Fig. 1). 
Fig. 1. Representative hematoxylin and eosin staining of the HN-
SCC center of the tumor (CT), zone of invasion (ZI), and adjacent 
non-neoplastic epithelial tissues (AE). Original magnification 200×. 
SOURCE: Oral Pathology FO/UFRGS.
Histological grading was performed according to the 
criteria of Bryne et al. (8) by two pathologists (A.P.C.F 
and K.B.D), in which a score was attributed for each 
morphological characteristic being evaluated, and in-
dividual scores were combined to determine to which 
group of malignancy the specimen belonged: low, mod-
erate, or high.
-Clinical Staging
Clinical data of the tumors, such as tumor size (T), node 
status (N), and the presence of metastases (M),were 
tabulated and classified according to the TNM system, 
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following the parameters established by The American 
Joint Committee on Cancer, during the examination of 
the surgical specimens (pTNM) (9). The outcome of 5 
years of follow-up was classified as failure (local recur-
rence, regional or distant metastasis and death due to 
tumor) or disease-free survival (7).
-Immunohistochemistry
Histological sections of 3 µm were made using silanized 
slides for immunostaining of the MII isoforms (A, B, 
and C). Initially, the cuts were deparaffinized in xylol, 
rehydrated in a gradient of alcohol and water, and im-
mersed in 3% hydrogen peroxide solution to block the 
endogenous peroxidase activity. Afterwards, they were 
submitted to antigen retrieval and incubated with pri-
mary antibodies anti-MIIA, anti-MIIB, and anti-MIIC 
(IIA, polyclonal; IIB, clone D8H8; IIC, clone D4A7; 
rabbit antibodies; Cell Signaling; 1:50 dilution). Anti-
gen retrieval of the anti-MIIA epitope was conducted 
by incubation in a pressure cooker at 120°C for 3 min-
utes and of the anti-MII B and C epitopes by treatment 
with 0.25% trypsin for 30 minutes. Incubation of all 
antibodies was conducted at 4°C overnight. A posi-
tive control (stomach adenocarcinoma) and a negative 
control (non-immune serum from the same animal spe-
cies as the primary antibody) were used according to 
the manufacturer’s instructions. The detection system 
used was polymeric (Envision dual link; Dako, Carpen-
taria, CA, USA), and the samples were developed with 
a chromogen solution containing 0.03% 3-3,3′-diamino-
benzidine (DAB, DakoCytomation, USA). The samples 
were counterstained with a solution of Mayer’s hema-
toxylin. 
-Data Analysis
Tumoral cells that presented brown cytoplasmic stainin-
gwere considered positive for MIIA, MIIB, and MIIC. 
The immunostained histological cuts were submitted 
for semi-quantitative analysis based on the extent of 
immunoreactivity. Samples were considered positive 
when more than 30% of the tumor cells were marked. 
Immunohistochemical analysis was performed by two 
pathologists (A.P.C.F and K.B.D), and reproducibility 
was confirmed over the study period by randomly se-
lecting one out of every 10 slides for reassessment after 
a 7-day interval (kappa > 0.7). During the evaluation, 
examiners were blinded to the origin of the material.
-Statistical Analysis
Data were analyzed using SPSS version 21. The rela-
tionship between the immunostaining of the proteins 
was evaluated using the chi-squared test; the immunos-
taining distribution of the proteins in the tumoral zones 
according to the evolution, and exposure to alcohol and 
smoke were verified by Mann–Whitney tests. Kruskal–
Wallis tests were used to evaluate the distribution of the 
protein immunostaining in the tumoral zones, accord-
ing to the histological grading and pTNM system. To 
evaluate survival over the total time of monitoring and 
any connection to the studied proteins, Kaplan-Meier 
analysis was used. P values ≤0.05 were considered sta-
tistically significant.
Results
Among the patients evaluated, 85.2% were men and 
14.8% women, the mean age was 58.3, and the predomi-
nant age group was over 65 years old. The majority of 
the occurrences of HNSCC were in the mouth (68.5%) 
in relation to the patients affected in the neck (31.5%) 
(Table 1).
According to the pTNM system, 63% presented tumor 
sizes between T1 and T2, 64.8% did not present region-
al metastasis (N0), and there were no distant metasta-
ses (MX, M0, and M1) (Table 1). In advanced pTNM 
stages, the expression of MIIB in AE tended to increase 
(p = 0.057) (Table 1).
According to histological grading, 48.1% of the HN-
SCC samples were of moderate grade, and no statistical 
correlations between the expression of MIIs in the AE 
and the tumoral zones were observed (Table 1).
At the time of the diagnosis, 38.9% of the patients were 
exposed to tobacco and 48.1% to alcohol (Table 1). Of 
the patients exposed to alcohol, 83.3% had maintained 
their habit for a period longer than 10 years. At an av-
erage of 4.7 and 6.3 years before HNSCC diagnosis, 
55.5% of the patients had ceased tobacco use and 46.3% 
had stopped alcohol consumption, respectively.
There was no statistically significant correlation be-
tween exposure to tobacco and alcohol with protein 
expression. However, in patients exposed to alcohol, a 
correlation with immunostaining for MIIA (p = 0.048) 
and MIIB (p = 0.010) was found in the AE (Table 2). 
In tumoral zones, there was an association of high ex-
pression among the three isoforms (Table 2).
The maximum time of monitoring was 5.9 years, and 
from the total of 54 initial patients, we obtained the fi-
nal status for 46 patients. Among these patients, 58.1% 
showed positive evolution (disease free survival) and 
41.9% exhibited negative evolution (treatment failure). 
The average number of years for patients to present 
failure was 5.01.Negative clinical evolution in patients 
was directly correlated to increased MIIC expression (p 
= 0.017) (Table 3) in the ZI of the HNSCC cases (Fig. 
2). Based on the evolution after the monitoring period, 
patients with tumors with MIIC expression had poorer 
prognosis (p = 0.048) (Fig. 3). 
Discussion
The mean age of the patients assessed in this study was 
58.3 years, while 29.6% of patients were over 65 years 
old, in agreement with the literature (10). In the patient 
sample described, 85.2% were men, which correlates 
well with a 2- to 4-fold higher incidence of male suffer-
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Clinical Parameters n %
Age
Mean 58,3 - -





Gender Male 48 85,2
Female 08 14,8
Tobacco Current 21 38,9
Former 30 55,5
Never 03 5,60
Alcohol Current 26 48,1
Former 25 46,3
Never 03 5,60
Histological Grading Low 25 46,3
Moderate 26 48,1
High 03 5,60
Size T1/T2 34 63,0
T3/T4 20 37,0
Regional metastases N0 35 64,8
N1/N2/N3 19 35,2
Localization Mouth 37 68,5
Neck 17 31,5
Total 54 100
Table 1. Demographic data and tumor features.
ing from HNSCC in comparison to female, according to 
data described by Globocan (11).
The TNM system, although suggested as a useful tool 
for forming therapeutic decisions, is not indicated for 
prognostic prediction. This makes it necessary to ob-
tain more prognostic tools, such as markers related to 
the metastatic process (12). This was confirmed in this 
study, where the majority of patients were in the early 
stages (T1/T2 = 63%, N0 = 64.8%) and the evolution 
rate was highly negative (41.9%). We have to consider 
that one of the limitations of this study is that at the time 
of sample collection (2009) the condition of the patients 
in relation to HPV was not investigated since the HN-
SCC related to this viral infection predominate in the 
region of oropharynx and present different clinical, mi-
croscopic and molecular features (13). Only in the year 
2017 was the new TNM edition published, considering 
a different staging for HPV positive patients, confirm-
ing this condition as a limitation not only of this study 
but for the staging of the disease itself (14).
Corroborating studies that questioned the value of his-
tological grading as a predictive factor for prognosis 
(12), only 5.6% of HNSCC samples from this study had 
high histological grades, and the proportion of patients 
with good evolution (58.1%) was small.
Analysis of the behavioral profile of tumoral zones is 
indispensable since a cell population in the ZI of the 
HNSCC resembles that found in metastases (8). In addi-
tion, adhesion molecules can present a similar behavior 
involving tumoral zones and AE (15), indicating that 
molecular evaluation of AE may provide information 
concerning tumor behavior (6). Our results suggest that 
the more advanced pTNM stages correspond to higher 
MIIB immunoreactivity in AE (p = 0.057). Consider-
ing that tumors such as melanoma, with high potential 
for tissue invasion and metastasis, express high levels 
of MIIB (16), it is possible to suggest detection of MIIB 
expression in AE as a potential sign of regional metas-
tasis. Myosin IIB may contribute to cancer cell invasion 
by maintaining cell contractility, which is required for 
their passage through pores in the extracellular matrix 
(13,17). 
Traditionally, in 80-90% of patients suffering from 
HNSCC, the disease is related to alcohol and tobacco 
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Frequency of protein expression
Adjacent epithelium Tumoral zones
MIIA MIIB MIIC MIIA MIIB MIIC
n 38 35 41 44 42 38
% 70,4 64,8 75,9 81,5 77,8 70,4
Distribution and association of protein immunostaining






MIIA AE 45 83,3 0,347 0,253 0,472 0,048
CT 43 79,6 0,696 0,346 0,279 0,143
ZI 49 90,7 0,976 0,141 0,823 0,197
MIIB AE 44 81,5 0,057 0,359 0,792 0,010
CT 37 68,6 0,268 0,220 0,919 0,165
ZI 43 79,6 0,210 0,139 0,919 0,165
MIIC AE 44 81,5 0.426 0,379 0,759 0,546
CT 38 70,4 0,926 0,780 0,871 0,286
ZI 44 81,5 0,324 0,274 0,596 0,547
Association of the protein immunostaining in the Tumoral Zones
MIIA/MIIB MIIB/MIIC MIIA/MIIC
0,001 0,006 0,012
Table 2. Isoforms expression frequency and their associations.
* p values ≤ 0.05 were considered significant. TNM, histological graduation: Kruskal–Wallis test; Exposed to tobacco, exposed to 
alcohol: Mann–Whitney test; Association of protein immunostaining in tumoral zones: chi-square test.













n % n % n % p-value *
MIIA
AE 21 38,9 13 24 34 62,8 0,625
CT 21 38,9 12 22,2 33 61,1 0,954
ZI 24 44,4 15 27,5 39 72,2 0,179
MIIB
AE 20 37,0 13 24,0 33 61,0 0,806
CT 17 31,5 09 16,7 26 48,2 0,574
ZI 20 37,0 12 22,2 32 52,2 0,507
MIIC
AE 20 37,0 13 24,0 33 61,0 0,952
CT 18 33,3 09 16,6 27 49,9 0,247
ZI 20 37,0 13 24,0 33 61,0 0,017
Table 3. Clinical evolution and its relationship with protein immunostaining.
The “n” and percentages correspond to simultaneous immunostaining and to the final status of the patients; *Mann–Whitney test.
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exposure (18). A possible challenge to this assumption 
can be made based on the present sample since there 
were a number of patients who stopped their habits 
long before development of the disease. This decrease 
in the number of patients exposed to risk factors for 
HNSCC may be attributed to new initiatives in public 
health targeting the prevention of HNSCC and related 
illnesses (19). Nevertheless, we have to consider that 
an important number of our sample (31.5%) is of the 
Fig. 2. Representative images of MIIC immunolabeling in ZI of HNSCCs: A, B and C original mag-
nification 200×; D, E and F, highlighting cytoplasmic and nuclear marking. Original magnification 
400×. SOURCE: Oral Pathology FO/UFRGS.
neck region, and that, 70.4% of the sample was com-
posed by younger patients (below 65 years). Since HPV 
is related to the pathogenesis of the disease mostly in 
the oropharynx in younger patients (1), our data sug-
gest, that HNSCC development may have HPV as an 
etiological factor. Further studies are needed to define 
the role of HPV in HNSCC carcinogenesis; however, it 
is possible that interactions between HPV oncoproteins 
and cell cycle mediators lead to cell cycle progression, 
Med Oral Patol Oral Cir Bucal. 2019 May 1;24 (3):e346-53.                                                                                                                                  Non-muscle myosin II in head and neck carcinoma
e352
Fig. 3. Kaplan-Meier curve showing, according to the time of monitoring, the evolution 
of survival in patients with tumors showing MIIC expression (0.146, standard deviation, 
95% confidence.
cell immortalization, apoptosis suppression and essen-
tially decoupling of proliferation and maturation, caus-
ing the HNSCC (1).
A correlation was observed between immunostaining 
for MIIA (p = 0.048) and MIIB (p = 0.010) in AE in 
patients exposed to alcohol for periods longer than 10 
years. According to studies of the relationship between 
alcohol consumption and HNSCC, it was observed that 
chronic alcohol consumption can cause a reduction in 
epithelial thickness and consequently an increase in cel-
lular desquamation, causing an adaptive response of the 
epithelium and increasing the proliferation of the basal 
coat (20)  and the possibility of errors during DNA du-
plication. Additionally, proto-oncogenes as well as tu-
mor suppressor genes, which are altered during alcohol 
exposure, may influence the expression and/or regula-
tion of MII isoform activity (21,22). Considering that 
the damage caused by alcohol is related to the duration 
of exposure (20,23), since the cell has DNA damage and 
acquires tumoral behavior, it can assume a migratory 
phenotype by activation of MIIA and MIIB (24).
During cellular migration, there is cooperation between 
MIIA and MIIB because during the protrusion of the 
cellular body, MIIA is responsible for adhesion between 
cells and the extracellular environment, whereas MIIB 
is responsible for stabilization of adhesion complexes. 
This synergy may justify the fact that in the tumoral 
zones, increased MIIA expression is related to in-
creased MIIB expression (p = 0.001) (25).
The present study demonstrated the presence of MIIA 
in both AE and tumoral zones. However, it does not 
correlate this presence with either clinical staging or 
clinical outcome. Even so, it is important to note that 
the literature contains paradoxical findings regarding 
this protein (17). In pulmonary adenocarcinoma, it was 
observed that patients who did not present immunore-
activity to MIIA had no cancer recurrence for 5 years, 
concluding that non-expression of MIIA is a predic-
tive factor for good evolution, in agreement with other 
studies involving esophageal and stomach carcinomas 
(26,27). These studies appear to contradict the reports 
by Schramek et al.  (28) and Conti et al.  (29) that state 
that loss of MIIA appeared to be related to tumor initia-
tion.
MIIC is one of the proteins responsible for breaking 
intercellular bridges present during final cell division. 
Defects in this process may result in binucleated cells 
and alterations in the expression and/or activity of this 
protein, generating abnormal cytokinesis, which could 
foster the propagation of genetic defects such as aneu-
ploidy (30,31) in breast and pulmonary cancer cell lines. 
Takaoka et al. suggested that formation of the contrac-
tile ring at the last step of cell division depends on MIIC 
as a critical stage in cytokinesis, offering an explanation 
for how chromosomal instability may arise in breast 
cancer (32). This study showed that there was a worsen-
ing of the prognosis of patients whose tumors expressed 
MIIC (p = 0.048) (Fig. 2) and that negative evolution in 
patients was correlated to increased MIIC in the ZI (p 
= 0.017). Since tumoral progression occurs in the ZI, 
and because the physical forces generated by MIIC are 
necessary for cell division, we can suggest that MIIC 
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expression in the ZI is a predictive factor for the nega-
tive evolution of HNSCC patients in cases where the 
cause of clinical failure is tissue invasion (4). 
Although the role of MIIs in HNSCC progression is still 
not clear, the present work suggests that MIIB expres-
sion in AE may indicate the potential for regional me-
tastasis and that MIIC expression in the tumoral ZI is 
predictive of negative evolution of the disease.
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